ReviewCurrent opinion in systems biology2017
Quantitative systems pharmacology and the personalized drug-microbiota-diet axis.
Review in Current opinion in systems biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Microbiota-based PBPK model: new approach methodology for assessing the kinetics of drugs and chemicals.Frontiers in pharmacology · 2026Review
- Influence of probiotics and deoxycholate on azathioprine transport in the PAMPA model: insights into pharmacomicrobiomics and interindividual variability in drug response.Frontiers in pharmacology · 2025Article
- Microbiome modeling: a beginner's guide.Frontiers in microbiology · 2024Review
- Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine.Nature biotechnology · 2023Article
- Taxonomic and functional profiling of fecal metagenomes for the early detection of colorectal cancer.Frontiers in oncology · 2023Article
- Impact of Contaminants on Microbiota: Linking the Gut-Brain Axis with Neurotoxicity.International journal of environmental research and public health · 2022Review
- Gut Microbiota Metabolism of Azathioprine: A New Hallmark for Personalized Drug-Targeted Therapy of Chronic Inflammatory Bowel Disease.Frontiers in pharmacology · 2022Review
- Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity.Frontiers in pharmacology · 2021Review
- Advances in flux balance analysis by integrating machine learning and mechanism-based models.Computational and structural biotechnology journal · 2021Review
- The Microbiome and the Gut-Liver-Brain Axis for Central Nervous System Clinical Pharmacology: Challenges in Specifying and Integrating In Vitro and In Silico Models.Clinical pharmacology and therapeutics · 2020Review
- PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.Journal of pharmacokinetics and pharmacodynamics · 2020Article
- Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions.BMC biology · 2020Article
- Personalized whole-body models integrate metabolism, physiology, and the gut microbiome.Molecular systems biology · 2020Article
- Dynamical systems approaches to personalized medicine.Current opinion in biotechnology · 2019Review
- Bringing microbiome-drug interaction research into the clinic.EBioMedicine · 2019Review
- Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease.Microbiome · 2019Article
- Review
- Drug Repositioning for Effective Prostate Cancer Treatment.Frontiers in physiology · 2018Review
- From metagenomic data to personalized in silico microbiotas: predicting dietary supplements for Crohn's disease.NPJ systems biology and applications · 2018Article
- Integration of constraint-based modeling with fecal metabolomics reveals large deleterious effects ofGut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine is an emerging paradigm that aims at maximizing the benefits and minimizing the adverse effects of drugs. Realistic mechanistic models are needed to understand and limit heterogeneity in drug responses. While pharmacokinetic models describe in detail a drug's absorption and metabolism, they generally do not account for individual variations in response to environmental influences, in addition to genetic variation. For instance, the human gut microbiota metabolizes drugs and is modulated by diet, and it exhibits significant variation among individuals. However, the influence of the gut microbiota on drug failure or drug side effects is under-researched. Here, we review recent advances in computational modeling approaches that could contribute to a better, mechanism-based understanding of drug-microbiota-diet interactions and their contribution to individual drug responses. By integrating systems biology and quantitative systems pharmacology with microbiology and nutrition, the conceptually and technologically demand for novel approaches could be met to enable the study of individual variability, thereby providing breakthrough support for progress in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.